Quantcast
Last updated on April 16, 2014 at 13:58 EDT

Latest Nerve conduction study Stories

2014-01-13 23:01:33

Wimbledon Health Partners, a leading on-site diagnostic testing company providing physicians’ vascular, echocardiogram and NCV testing announced expanded services in New York state. As of February 1st, Wimbledon Health Partners will now be offering needle EMGs in coordination with the existing NCV testing. Boca Raton, Florida (PRWEB) January 13, 2014 Wimbledon Health Partners, a leading on-site diagnostic testing company providing physicians’ vascular, echocardiogram and NCV testing...

2013-08-31 23:04:29

Hands-On News reports acclaimed doctor gave Astoria residence helpful tips about their foot health and how they can recover from ailments. Astoria, New York (PRWEB) August 31, 2013 The average person walks “about five miles a day, and over the course of an average lifetime that's 115 thousand miles, that's four times the circumference of the Earth.” No wonder our feet hurt. That is just one of the interesting facts that noted Podiatrist Dr. Ryan Minara spoke about to a group...

2013-05-16 23:26:53

For National Neuropathy Awareness Week (May 13-17), The Neuropathy Association and the Hereditary Neuropathy Foundation Call Attention to the Diagnostic Challenges Hurting Millions of Neuropathy Patients. New York, NY (PRWEB) May 16, 2013 Continued lack of peripheral neuropathy awareness combined with Medicare reimbursement cuts for diagnostic tools are causing major impediments to neuropathy epidemic prevention, patient care, and treatments according to The Neuropathy Association and the...

2011-09-12 03:00:00

MELBOURNE, Australia, September 12, 2011 /PRNewswire/ -- EMA401 Shown to Improve Nerve and Neurovascular Function Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy. EMA401 is an angiotensin II type 2 (AT2) receptor antagonist currently in clinical development for a number of neuropathic pain indications. The new data were presented at the 21st...

2011-08-26 16:00:00

Integrated Practice Resources, LLC to Provide Illinois Medical Professionals With On-Site Needle EMG, NCV And In-Office Electrodiagnostic (EDX) Testing. Boca Raton, Florida (PRWEB) August 26, 2011 Eric Gliniecki, Chief Operating Officer, today announced in a continued effort to serve its clients and insurance company protocols, the launch of physician-directed Needle EMG along with NCVs for its in-office clientele in Illinois. Integrated Practice Resources, LLC, is the...

2011-08-18 00:00:42

Are doctors missing the mark...not treating the real cause of your nerve pain? Buffalo Grove, IL (PRWEB) August 17, 2011 A Buffalo Grove IL doctors office has introduced a new and different protocol to help patients with foot pain and burning. Buffalo Grove Pain Relief Center near Arlington Heights and Buffalo Grove has a specialized exam and evaluation to find the true cause of this problem, thereby, helping the team of doctors and practitioners deliver the right treatment of this painful...

2011-07-28 00:01:01

For many relief is not received because the treatment is flawed, or because the cause is not found. Louisville, KY (PRWEB) July 27, 2011 A Louisville doctor has introduced a new protocol to help patients with foot pain, numbness and burning. Dr. Paul Constante and staff of Dynamic Medical and Rehab in Louisville has a specialized exam and evaluation to find the true cause of the problem, thereby, helping his team of doctors and practitioners deliver the proper treatment of this painful and...

2010-06-29 06:00:00

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA), held in Orlando, FL from June 25-29, 2010. Data from Sangamo's SB-509-601 and SB-509-701B Phase 2 clinical trials demonstrated that SB-509 treatment resulted in clinically...

2010-04-15 09:03:12

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range. In a related study of peripheral nerve function, the same group found that aging affects the nerves of men more than women later in life. The findings imply, the researchers say,...

2009-10-20 13:00:00

RICHMOND, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of top-line, statistically significant Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the Society for Neuroscience Annual Meeting held in Chicago. Top-line data from Sangamo's SB-509-601 Phase 2 clinical trial demonstrated a direct neuroregenerative effect of SB-509 treatment that...